1. Academic Validation
  2. Selective inhibition of BET bromodomains

Selective inhibition of BET bromodomains

  • Nature. 2010 Dec 23;468(7327):1067-73. doi: 10.1038/nature09504.
Panagis Filippakopoulos 1 Jun Qi Sarah Picaud Yao Shen William B Smith Oleg Fedorov Elizabeth M Morse Tracey Keates Tyler T Hickman Ildiko Felletar Martin Philpott Shonagh Munro Michael R McKeown Yuchuan Wang Amanda L Christie Nathan West Michael J Cameron Brian Schwartz Tom D Heightman Nicholas La Thangue Christopher A French Olaf Wiest Andrew L Kung Stefan Knapp James E Bradner
Affiliations

Affiliation

  • 1 Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, UK.
Abstract

Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying Enzymes, or so-called epigenetic 'writers' and 'erasers'. Potent inhibitors of histone binding modules have not yet been described. Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains. High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity. Recurrent translocation of BRD4 is observed in a genetically-defined, incurable subtype of human squamous carcinoma. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models. These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chemical scaffold for the development of chemical probes more broadly throughout the bromodomain family.

Figures
Products